NCT06899906
- Conditions
- Efficacy and Safety of Dalbavancin, For Acute or Chronic Infections Between July 2019 and December 2024, In Subjects Who Received SAT with DAL
- Locations
-
- HCL France, Lyon
Clinical trial condition
For Acute or Chronic Infections Between July 2019 and December 2024
Explore clinical trials studying For Acute or Chronic Infections Between July 2019 and December 2024. Study availability and eligibility vary by location and protocol.
1 public trial
1 recruiting study